Glycine transporter type 1 occupancy by bitopertin: A positron emission tomography study in healthy volunteers

Neuropsychopharmacology

Volumn 38, Issue 3, 2013, Pages 504-512

  Martin Facklam, Meret ^a   Pizzagalli, Flavia ^a   Zhou, Yun ^b   Ostrowitzki, Susanne ^a   Raymont, Vanessa ^b   Brašić, James R ^b   Parkar, Nikhat ^a   Umbricht, Daniel ^a   Dannals, Robert F ^b   Goldwater, Ron ^c   Wong, Dean F ^b  

^a Pharma Research   (Switzerland)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c PAREXEL INTERNATIONAL   (United States)

Author keywords

bitopertin; glycine reuptake inhibitor; glycine transporter 1; N methyl D aspartate; Receptors; RG1678; schizophrenia

Indexed keywords

BITOPERTIN; GLYCINE TRANSPORTER 1;

ADULT; ARTICLE; CEREBELLUM; DRUG DISTRIBUTION; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; MALE; NORMAL HUMAN; OPEN STUDY; PARALLEL DESIGN; PONS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RELIABILITY; STEADY STATE; THALAMUS;

ADMINISTRATION, INTRAVENOUS; ADULT; BRAIN; GLYCINE PLASMA MEMBRANE TRANSPORT PROTEINS; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; POSITRON-EMISSION TOMOGRAPHY; SULFONES; YOUNG ADULT;

EID: 84872495665     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2012.212     Document Type: Article

References (35)

1. Alberati D, Moreau JL, Lengyel J, Hauser N, Mory R, Borroni E et al (2012). Glycine reuptake inhibitor RG1678: a pharmacologic characterization of an investigational agent for the treatment of schizophrenia. Neuropharmacology 62: 1152-1161.
2. Borroni E, Zhou Y, Ostrowitzki S, Alberati D, Kumar A, Hainzl D et al (2011). Pre-clinical characterization of [11C]R05013853 as a novel radiotracer for imaging of the Glycine Transporter type 1 by Positron Emission Tomography Neuroimage; e-pub ahead of print 10 December2011. doi:10.1016/j.neuroimage.2011. 11.090.
3. Cubelos B, Giménez C, Zafra F (2005). Localization of the GLYT1 glycine transporter at glutamatergic synapses in the rat brain. Cereb Cortex 15: 448-459.
4. Cunningham VJ, Matthews JC, Gunn RN, Rabiner EA, Gee AD (2004). Identification and interpretation of microparameters in neuroreceptor compartmental models. Neuroimage 22(Suppl. 2): T13-T14.
5. Cunningham VJ, Rabiner EA, Slifstein M, Laruelle M, Gunn RN (2010). Measuring drug occupancy in the absence of a reference region: the Lassen plot re-visited. J Cereb Blood Flow Metab 30: 46-50.
6. Depoortère R, Dargazanli G, Estenne-Bouhtou G, Coste A, Lanneau C, Desvignes C et al (2005). Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic Neuropsychopharmacology 30: 1963-1985.
7. Friston K (2002). Statistical parametric mapping 2. http://www. fil.ion.ucl.ac.uk/spm/software/spm2/.
8. Gunn RN, Murthy V, Catafau AM, Searle G, Bullich S, Slifstein M et al (2011). Translational characterization of [(11)C] GSK931145, a PET ligand for the glycine transporter type 1 (GlyT1-1). Synapse 65: 1319-1332.
9. Hamill TG, Eng W, Jennings A, Lewis R, Thomas S, Wood S et al (2011). The synthesis and preclinical evaluation in rhesus monkey of [(18)F]MK-6577 and [(11)C]CMPyPB, glycine transporter 1 positron emission tomography radiotracers. Synapse 65: 261-270.
10. Herdon HJ, Roberts JC, Coulton S, Porter RA (2010). Pharmaco-logical characterisation of the GlyT-1 glycine transporter using two novel radioligands. Neuropharmacology 59: 558-565.
11. Hilton J, Yokoi F, Dannals RF, Ravert HT, Szabo Z, Wong DF (2000). Column-switching HPLC for the analysis of plasma in PET imaging studies. Nucl Med Biol 27: 627-630.
12. Hofmann C, Alberati D, Banken L, Boetsch C, Ereshefsky L, Jhee S et al (2011). Glycine transporter type 1 (GlyT1) inhibitor RG1678: proof of mechanism of action in healthy volunteers. Schizophr Bull 37(Suppl 1): 306.
13. Innis RB, Cunningham VJ, Delforge J, Fujita M, Giedde A, Gunn RN et al (2007). Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 27: 1533-1539.
14. Javitt DC (2006). Is the glycine site half saturated or half unsaturated? Effects of glutamatergic drugs in schizophrenia patients. Curr Opin Psychiatry 19: 151-157.
15. Javitt DC (2007). Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate inter-actions. Int Rev Neurobiol 78: 69-108.
16. Javitt DC (2009). Glycine transport inhibitors for the treatment of schizophrenia: symptom and disease modification. Curr Opin Drug Discov Devel 12: 468-478.
17. Koeppe RA, HolthoffVA, FreyKA, Kilbourn MR, Kuhl DE (1991). Compartmental analysis of [11C]flumazenil kinetics for the estimation of ligand transport rate and receptor distribution using positron emission tomography. J Cereb Blood Flow Metab 11: 735-744.
18. Lammertsma AA, Hume SP (1996). Simplified reference tissue model for PET receptor studies. Neuroimage 4: 153-158.
19. Lassen NA, Bartenstein PA, Lammertsma AA, Prevett MC, Turton DR, Luthra SK et al (1995). Benzodiazepine receptor quantifica-tion in vivo in humans using [11C]flumazenil and PET: application of the steady-state principle. J Cereb Blood Flow Metab 15: 152-165.
20. Logan J, Fowler JS, Volkow ND, Wolf AP, Dewey SL, Schlyer DJ et al (1990). Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab 10: 740-747.
21. Patlak CS, Blasberg RG, Fenstermacher JD (1983). Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab 3: 1-7.
22. Patlak CS, Blasberg RG (1985). Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations. J Cereb Blood Flow Metab 5: 584-590.
23. Pinard E, Alanine A, Alberati D, Bender M, Borroni E, Bourdeaux P et al (2010). Selective GlyT1 inhibitors: discovery of [4-(3-fluoro-5- trifluoromethylpyridin-2-yl)piperazin-1-yl][5-methanesulfonyl-2-((S)-2,2, 2-trifluoro-1-methylethoxy)phenyl]methanone (RG1678), a promising novel medicine to treat schizophrenia. JMed Chem 53: 4603-4614.
24. Pinard E, Burner S, Cueni P, Hartung T, Norcross RD, Schmid P et al (2011). Radiosynthesis of [5-[11C]methanesulfonyl-2-((S)-2,2,2-trifluoro-1- methyl-ethoxy)-phenyl]-[5-(tetrahydro-pyran-4-yl)-1,3-dihydro-isoindol-2-yl] -methanone ([11C]RO5013853), a novel PET tracer for the glycine transporter type I (GlyT1). J Labelled Comp Radiopharm 54: 702-707.
25. Smith KE, Borden LA, Hartig PR, Branchek T, Weinshank RL (1992). Cloning and expression of a glycine transporter reveal colocalization with NMDA receptors. Neuron 8: 927-935.
26. Tauscher J, Jones C, Remington G, Zipursky RB, Kapur S (2002). Significant dissociation of brain and plasma kinetics with antipsychotics. Mol Psychiatry 7: 317-321.
27. Uppoor RS, Mummaneni P, Cooper E, Pien HH, Sorensen AG, Collins J et al (2008). The use of imaging in the early development of neuropharmacological drugs: a survey of approved NDAs. Clin Pharmacol Ther 84: 69-74.
28. Wong DF, Nestadt G, Cumming P, Yokoi F, Gjedde A (2000). Partition volume and regional binding potentials of serotonin receptor and transporter ligands. In: Gjedde A, Hansen SB, Knudsen GM, Pavison OB (eds). Physiological Imaging of the Brain with PET. Academic Press: San Diego, pp 257-263.
29. Wong DF, Ostrowitzki S, Zhou Y, Raymont V, Hofmann C, Borroni E et al (2011). Characterization of [11C]RO5013853, a novel PET tracer for the glycine transporter Type 1 (GlyT1) in humans. Neuroimage; e-pub ahead of print 1 December 2011. doi:10.1016/ j.neuroimage.2011.11.052.
30. Zafra F, Aragón C, Olivares L, Danbolt NC, Giménez C, Storm-Mathisen J (1995). Glycine transporters are differentially expressed among CNS cells. J Neurosci 15: 3952-3969.
31. Zeng Z, O'Brien JA, Lemaire W, O'Malley SS, Miller PJ, Zhao Z et al (2008). A novel radioligand for glycine transporter 1: Character-ization and use in autoradiographic and in vivo brain occupancy studies. Nucl Med Bio 35: 315-325.
32. Zhou Y, Endres CJ, Bras?ić JR, Huang SC, Wong DF (2003). Linear regression with spatial constraint to generate parametric images of ligand-receptor dynamic PET studies with a simplified reference tissue model. Neuroimage 18: 975-989.
33. Zhou Y, Resnick SM, Ye W, Fan H, Holt DP, Klunk WE et al (2007). Using a reference tissue model with spatial constraint to quantify [11C]Pittsburgh compound B PET for earlydiagnosis of Alzheimer's disease. Neuroimage 36: 298-312.
34. Zhou Y, Ye W, Bras?ic JR, Crabb AH, Hilton J, Wong DF (2009). A consistent and efficient graphical analysis method to improve the quantification of reversible tracer binding in radioligand receptor dynamic PET studies. Neuroimage 44: 661-670.
35. Zhou Y, Ye W, Bras?ić JR, Wong DF (2010). Multi-graphical analysis of dynamic PET. Neuroimage 49: 2947-2957.